Congressional leadership elections take place largely outside public view, yet the politicians selected help determine which healthcare reforms advance. Research on lobbying, campaign contributions, and political access raises questions about whose priorities receive attention. Following the 2026 midterm elections, voters have an opportunity to examine how their representatives make those choices.
Key Takeaways
- Americans elect members of Congress, but lawmakers choose their party leaders through internal elections.
- Congressional leaders influence legislative priorities, negotiations, and the scheduling of bills, including healthcare proposals.
- Healthcare organizations spent $713.6 million on federal lobbying in 2020, according to a peer-reviewed study.
- A randomized experiment found that identifying meeting attendees as campaign donors increased their access to senior congressional officials.
- The November 2026 elections gave Democrats control of both chambers, but leadership elections, Senate procedures, and presidential veto powers will still shape healthcare legislation.
- Voters can contact newly elected lawmakers, ask about leadership priorities, and monitor healthcare legislation after Election Day.
Introduction: The Healthcare Decisions Voters Do Not Directly Make
Congressional party leaders influence legislative priorities, including proposals affecting healthcare costs, insurance coverage, and prescription drug prices.
Americans vote for lawmakers who promise to reduce prescription drug prices, improve insurance coverage, and make medical care more affordable. But once an election ends, another important political process begins: members of Congress choose the leaders who will help shape their legislative agenda.
These internal elections receive far less public attention than general elections. Yet congressional leaders influence which bills receive consideration, how negotiations proceed, and which healthcare priorities their parties pursue.
For patients struggling with medical bills, insurance denials, or expensive medications, those decisions can have consequences.
Congressional leaders do not control healthcare policy on their own. Committees, individual lawmakers, procedural rules, and the president all influence whether legislation advances.
Research also shows that healthcare organizations invest substantial resources in lobbying and campaign contributions, while experimental evidence indicates that donor status can improve access to senior congressional officials.
These findings do not establish that healthcare companies determine congressional leadership elections. They do, however, raise important questions about political access, fundraising incentives, and public accountability.
Understanding how leaders are chosen can help voters assess whether their representatives’ decisions reflect the healthcare priorities they supported during the election.
How Congressional Leaders Are Chosen and Why It Matters
House Democrats and Republicans select their party leaders through their respective caucuses and conferences. Senate Democrats and Republicans follow similar internal procedures.
The House Speaker is formally elected by the full House.
Voters do not directly participate in these internal party elections.
A congressional leader may therefore remain in a leadership position despite public dissatisfaction if enough fellow lawmakers continue providing support.
The arrangement allows legislators to organize their work, but it also creates an additional layer between voters and the people directing congressional business.
Party leaders coordinate legislative priorities, negotiate with colleagues, and help determine which proposals receive floor consideration.
In the House, majority-party leadership has substantial influence over the legislative schedule. In the Senate, the majority leader organizes floor business while operating within rules that give individual senators and minority-party members considerable procedural influence.
A healthcare proposal cannot become law simply because voters support it. It must move through the legislative process and secure enough support to pass both chambers.
Leadership decisions can affect that process.
Why Fundraising Relationships Matter
Congressional leaders are expected to help their parties compete in elections.
That includes raising money, maintaining political relationships, and assisting colleagues facing difficult campaigns.
When lawmakers select party leaders, they may consider a candidate’s ability to help the party retain or gain congressional seats.
Experience, ideology, legislative strategy, and relationships with colleagues also matter.
But fundraising creates a potential tension between political success and policy responsiveness.
A leadership candidate may offer valuable financial and organizational support to fellow lawmakers without necessarily sharing the healthcare priorities emphasized by their constituents.
The concern becomes especially relevant when Congress considers legislation affecting industries with substantial financial resources.
Pharmaceutical manufacturers, health insurers, hospitals, and other healthcare organizations all have interests in federal policies governing prices, coverage, reimbursement, and regulation.
Patients also have interests in those decisions, but their ability to finance sustained political advocacy is often much more limited.
Healthcare Companies Spend Hundreds of Millions on Lobbying
In a 2022 study published in JAMA Health Forum, Schpero and colleagues examined federal lobbying expenditures across healthcare industries from 2000 through 2020.
Using OpenSecrets data, the researchers found that healthcare organizations spent $713.6 million on federal lobbying in 2020, adjusted to 2020 dollars.
| Healthcare industry | 2020 lobbying expenditures |
|---|---|
| Pharmaceutical and health product manufacturers | $308.4 million |
| Healthcare providers | $286.9 million |
| Insurers and other payer organizations | $80.6 million |
| Other healthcare organizations | $37.7 million |
| Total | $713.6 million |
Lobbying expenditures were concentrated among a relatively small number of organizations.
In 2020, the highest-spending 10% of payer organizations accounted for 70.4% of lobbying expenditures in that category. The corresponding shares were 69.0% for pharmaceutical and health product manufacturers and 59.0% for healthcare providers.
Across the four healthcare industry categories examined, inflation-adjusted lobbying expenditures increased by more than 70% between 2000 and 2020, with faster growth occurring before 2010.
These findings document the scale and concentration of healthcare lobbying during the study period. They do not establish that higher expenditures caused particular legislative outcomes or influenced congressional leadership elections.
The researchers also identified limitations in the underlying disclosure data. Reporting thresholds may exclude some lobbying activities, and certain organizations’ disclosures may include state-level or grassroots lobbying expenditures. Classifying organizations with both healthcare and non-healthcare business activities can also be difficult.
The figures describe historical spending through 2020 and should not be interpreted as estimates of healthcare lobbying expenditures in 2026.
Pharmaceutical Contributions Reach Influential Lawmakers
A separate investigation examined pharmaceutical industry political spending over two decades.
In a 2020 study published in JAMA Internal Medicine, Wouters analyzed lobbying expenditures and campaign contributions by the pharmaceutical and health product industry between 1999 and 2018.
The industry spent approximately $4.7 billion lobbying the federal government during that period, measured in inflation-adjusted 2018 dollars.
It also directed approximately $414 million toward federal candidates, national party committees, and outside spending groups.
Among the 20 senators and 20 House representatives who received the largest contributions from the industry, 39 served on committees with jurisdiction over healthcare-related legislation.
Twenty-four held senior committee positions.
These relationships matter because congressional committees help develop, evaluate, and revise healthcare proposals.
The study was descriptive and could not establish that campaign contributions caused specific legislative decisions.
It also did not examine whether pharmaceutical contributions influenced internal party leadership elections.
Nevertheless, it documented substantial political spending directed toward lawmakers positioned to affect healthcare policy.
Research Shows That Donor Status Can Improve Access
Political contributions may influence more than election campaigns. Experimental research shows that being identified as a campaign donor can improve access to congressional decision-makers.
In a 2016 study published in the American Journal of Political Science, political scientists Joshua Kalla and David Broockman conducted a randomized field experiment involving 191 congressional offices.
The researchers examined meeting requests made on behalf of an organization whose members had contributed to political campaigns. They randomly varied whether congressional offices were informed about the prospective attendees’ donor status.
When offices were told that attendees were campaign donors, 18.8% of the groups obtained meetings involving senior congressional staffers.
When attendees were presented only as constituents, 5.5% obtained comparable access.
Access to members of Congress or chiefs of staff was also more common when donor status was disclosed: 12.5% compared with 2.4%.
Because the researchers randomly varied whether donor status was revealed, the experiment provided evidence that this information influenced access.
However, the study did not establish that donations changed congressional votes, secured favorable legislation, or influenced internal party leadership elections. It also did not specifically examine healthcare organizations.
Its relevance to healthcare policy lies in the broader question of access.
Pharmaceutical companies, insurers, hospitals, patient organizations, and individual constituents may all seek meetings with congressional officials to explain their concerns.
The experiment provides evidence that disclosing donor status can improve access to influential congressional officials. Whether this additional access changes healthcare policy, legislative votes, or congressional leadership decisions requires separate investigation.
For patients and voters, the distinction matters: access is not the same as legislative influence, but it creates opportunities to present arguments and participate in policy discussions.
How Healthcare Reform Can Stall Without a Public Vote
A healthcare proposal can fail without Congress ever formally rejecting it.
Consider legislation intended to reduce administrative barriers to medical treatment.
Patients and healthcare professionals might support the proposal because they believe it would reduce delays in care.
Insurers might raise concerns about implementation, administrative costs, or the effect on premiums.
Lawmakers would then need to evaluate competing arguments.
But the proposal’s fate would depend on more than those arguments.
It would need legislative sponsors, committee consideration, negotiations, and a place on the congressional calendar.
At any stage, it could be narrowed, delayed, or abandoned.
Such outcomes may reflect legitimate policy disagreements, budget constraints, or insufficient legislative support. They may also occur amid intensive lobbying by organizations whose financial interests are affected.
Without evidence concerning a specific proposal, it would be inappropriate to claim that industry pressure caused its failure.
The broader accountability problem remains: voters may find it difficult to determine why a healthcare reform never received a final vote.
Medicare Drug Negotiation Shows That Reform Is Possible
Healthcare industry lobbying does not always prevent legislation from passing.
The Inflation Reduction Act of 2022 established a Medicare drug-price negotiation program despite opposition from parts of the pharmaceutical industry.
According to the Centers for Medicare & Medicaid Services, the first negotiated prices, covering 10 selected Medicare Part D drugs, took effect on January 1, 2026.
This demonstrates that Congress can enact healthcare reforms even when financially powerful organizations oppose them.
It also shows why legislative details matter.
The program applies to selected medicines under defined eligibility rules and operates through a phased process.
Its effects depend on which drugs qualify, how negotiated prices are implemented, and the circumstances of individual Medicare beneficiaries.
Evaluating political influence therefore requires examining not only whether legislation passes but also how proposals change during negotiations.
Did Citizens United Make Healthcare Politics More Unequal?
The Supreme Court’s 2010 decision in Citizens United v. Federal Election Commission expanded the ability of corporations and labor unions to finance independent political expenditures.
Together with subsequent legal developments, the ruling contributed to a campaign finance environment in which super PACs can receive unlimited contributions for independent electoral activity.
The decision did not authorize unlimited direct corporate contributions to federal candidates.
The Federal Election Commission’s explanation of Citizens United describes the ruling’s effect on independent expenditures.
The decision also did not create healthcare lobbying, which was already substantial before 2010.
Indeed, Schpero and colleagues (2022) found that healthcare lobbying expenditures grew more rapidly before 2010 than afterward.
It would therefore be inaccurate to attribute the industry’s lobbying growth directly to Citizens United.
The ruling nevertheless matters to the broader debate because it expanded opportunities for wealthy interests to participate financially in elections.
The concern is whether an increasingly expensive political environment places greater value on fundraising relationships, including when lawmakers select their leaders.
That remains a question requiring direct evidence rather than a causal relationship established by the healthcare studies discussed here.
The 2026 Elections Make Congressional Leadership Choices Especially Relevant
The November 3, 2026, midterm elections gave Democrats majorities in both the House of Representatives and the Senate, according to Reuters reporting published November 4.
Although some individual races may still be undergoing final tabulation or certification, the reported results establish that Democrats are positioned to control both chambers when the 120th Congress convenes on January 3, 2027.
Democratic lawmakers are positioned to control the leadership of both chambers.
House Democratic leader Hakeem Jeffries is expected to become Speaker, subject to the formal House vote, while Senate Democratic leader Chuck Schumer is expected to seek continued leadership of his party.
These outcomes are not automatic. Party lawmakers must still choose their leaders through internal elections, and the full House must elect its Speaker.
The leadership transition is particularly relevant to healthcare policy.
Democratic leaders have identified affordability as a priority, while debates involving Medicaid, insurance coverage, and prescription drug costs are expected to remain prominent.
However, Democratic control of Congress does not guarantee that particular healthcare reforms will become law.
Most legislation in the Senate remains subject to procedural requirements that can make bipartisan support necessary.
President Donald Trump, a Republican, will also retain the power to veto legislation, subject to Congress’s constitutional authority to override a veto.
The incoming congressional leadership will therefore need to balance policy priorities, internal party disagreements, legislative procedures, and negotiations with the executive branch.
For voters, the leadership selection process offers an opportunity to ask which healthcare proposals their representatives want Congress to prioritize and how they intend to pursue those goals.
The important question is not simply who receives a leadership title, but how that leader uses congressional authority once in office.
Voter Guide: How to Influence Congressional Leadership After Election Day
Although voters cannot directly cast ballots in congressional party leadership elections, they can communicate with the lawmakers who participate in those decisions.
The period between November’s election and the start of the next Congress offers a particularly relevant opportunity.
1. Find Out When Leadership Elections Will Take Place
Congressional parties generally hold internal leadership elections after the November general election and before the new Congress convenes in January.
Exact dates differ by chamber and party.
According to Roll Call, House and Senate Republicans scheduled leadership elections for November 10, 2026.
Citizens interested in the process can follow official party announcements and congressional reporting to learn when leadership contests are scheduled.
2. Contact Your Representative or Senators
The most direct route for constituents is through their elected lawmakers.
Official contact information is available from:
During the transition, a newly elected House member may not appear in the official House directory until the new Congress begins.
Constituents can look for publicly announced contact information from the member-elect.
For senators, voters should distinguish between senators whose terms are continuing and those newly elected for the next Congress.
3. Ask Specific Questions About Healthcare Priorities
Questions about leadership selection can focus on the criteria lawmakers use.
For example:
- Which healthcare priorities should congressional leaders address first?
- What qualifications matter most when selecting a party leader?
- How important is fundraising ability in that decision?
- How should leaders respond when patient concerns conflict with healthcare industry positions?
- Will the lawmaker publicly explain the reasons for supporting a leadership candidate?
Specific questions can help constituents evaluate a lawmaker’s public statements against subsequent legislative activity.
4. Understand Which Leadership Votes Are Public
Many internal party leadership elections use secret ballots.
That means constituents may not be able to verify how an individual lawmaker voted in a particular internal contest.
The election of the House Speaker is different. It takes place on the House floor, and recorded votes can be examined.
For other leadership positions, voters can review public endorsements, statements, and explanations offered by lawmakers.
A lawmaker may choose not to disclose a secret-ballot vote, but constituents can still ask about the priorities and qualifications that informed the decision.
5. Participate in Public Meetings
Town halls, district meetings, and constituent forums provide opportunities to discuss congressional leadership and healthcare policy.
Patients, healthcare professionals, employers, and other community members can present different perspectives on proposed legislation.
These discussions do not guarantee changes in leadership votes.
They can, however, help lawmakers understand which healthcare concerns their constituents consider important.
6. Examine Political Contributions and Lobbying Records
Federal campaign finance records can help voters understand political fundraising relationships.
The Federal Election Commission publishes information about contributions, political committees, and independent expenditures.
Federal lobbying disclosures are publicly available through the Senate Lobbying Disclosure Act database.
These records can help citizens examine which organizations are financially active in political debates.
However, a contribution or lobbying expenditure does not establish improper influence.
Financial information is most useful when considered alongside public statements, committee assignments, legislative records, and documented policy decisions.
7. Follow Healthcare Legislation After Leaders Are Chosen
Leadership accountability continues after internal elections conclude.
Citizens can use Congress.gov to follow healthcare bills, sponsors, committee activity, amendments, and recorded votes.
They can also compare lawmakers’ statements during leadership elections with their later positions on healthcare proposals.
Some legislative decisions occur through negotiations that are not fully visible to the public. That limitation makes it important to distinguish documented actions from assumptions about motives.
The objective is to understand what happened to a proposal and which institutions or lawmakers were responsible for decisions that can be verified.
What These Steps Can and Cannot Accomplish
Constituent contact, public meetings, and scrutiny of political spending do not guarantee a particular leadership outcome.
Lawmakers retain the authority to choose their party leaders, and internal party procedures can limit public transparency.
Nevertheless, voters can seek explanations, communicate policy priorities, and evaluate the subsequent conduct of their representatives.
Political accountability does not end when an election is over.
Leadership selection is another stage in the process through which voters’ preferences may influence congressional decisions.
What the Research Can and Cannot Tell Us
The studies discussed in this article examine different aspects of political influence.
Schpero and colleagues documented healthcare lobbying expenditures between 2000 and 2020. Wouters examined pharmaceutical industry lobbying and campaign contributions between 1999 and 2018. Kalla and Broockman experimentally tested whether identifying prospective meeting attendees as political donors improved access to congressional officials.
Together, these findings demonstrate the substantial financial resources devoted to healthcare advocacy and provide evidence that donor status can affect political access.
However, none of the studies directly examined how members of Congress choose their party leaders.
They also do not establish that healthcare industry contributions caused particular legislative decisions or prevented specific reforms from advancing.
Congressional decisions can reflect competing policy priorities, budget constraints, procedural requirements, political negotiations, and disagreements about proposed legislation.
Determining whether financial relationships improperly influenced a particular decision would require additional evidence connecting those relationships to identifiable actions.
The research therefore provides important context for evaluating political influence, rather than proof that healthcare organizations control congressional leadership or legislative outcomes.
Final Thoughts: Healthcare Accountability Continues After Election Day
Congressional leadership elections rarely receive the attention given to national elections, yet the lawmakers chosen to lead each chamber help shape which healthcare proposals receive consideration.
Research documents substantial healthcare industry spending on lobbying and political contributions. Experimental evidence also shows that campaign donor status can improve access to influential congressional officials.
These findings do not prove that financial interests control congressional leadership or determine healthcare legislation. They do, however, demonstrate why transparency and public accountability matter.
For voters concerned about prescription drug prices, insurance coverage, and medical costs, participation does not have to end at the ballot box.
As the next Congress prepares to take office, constituents can ask their representatives how they evaluate leadership candidates, which healthcare priorities they support, and how they intend to hold congressional leaders accountable.
The future of American healthcare depends on more than who wins an election. It also depends on the decisions elected lawmakers make afterward, and whether voters continue paying attention.
Funding and Disclosures
Schpero and colleagues (2022) reported that their study was supported by grant 21-06179 from the Laura and John Arnold Foundation. The authors stated that the funder had no role in study design, data collection, analysis, interpretation, manuscript preparation, or the decision to publish.
Schpero, Carter, and Chatterjee reported research funding from public or nonprofit organizations outside the submitted work. No other disclosures were reported.
Wouters (2020) reported no conflicts of interest. No specific external funding source was identified in the published article.
Kalla and Broockman (2016) acknowledged support for Broockman from the National Science Foundation Graduate Research Fellowship Program.
References
Kalla, J. L., & Broockman, D. E. (2016). Campaign contributions facilitate access to congressional officials: A randomized field experiment. American Journal of Political Science, 60(3), 545–558. https://doi.org/10.1111/ajps.12180
Schpero, W. L., Wiener, T., Carter, S., & Chatterjee, P. (2022). Lobbying expenditures in the US health care sector, 2000–2020. JAMA Health Forum, 3(10), e223801. https://doi.org/10.1001/jamahealthforum.2022.3801
Wouters, O. J. (2020). Lobbying expenditures and campaign contributions by the pharmaceutical and health product industry in the United States, 1999–2018. JAMA Internal Medicine, 180(5), 688–697. https://doi.org/10.1001/jamainternmed.2020.0146
Additional Sources
Centers for Medicare & Medicaid Services. (2024). Medicare Drug Price Negotiation Program: Negotiated prices for initial price applicability year 2026. https://www.cms.gov/newsroom/fact-sheets/medicare-drug-price-negotiation-program-negotiated-prices-initial-price-applicability-year-2026
Federal Election Commission. Citizens United v. Federal Election Commission. https://www.fec.gov/updates/citizens-united-v-fecsupreme-court/
Reuters. (2026, November 4). Democrats seize Congress in sweeping midterm repudiation of Trump. https://www.reuters.com/legal/government/democrats-seize-congress-sweeping-midterm-repudiation-trump-2026-11-04/
Roll Call. (2026, October 30). Senate, House GOP set leadership elections. https://rollcall.com/2026/10/30/senate-house-gop-set-leadership-elections/
U.S. House of Representatives. Find your representative. https://www.house.gov/representatives/find-your-representative
U.S. Senate. Senators’ contact information. https://www.senate.gov/senators/senators-contact.htm
Editorial Verification Note
This article was published on November 5, 2026. Its discussion of healthcare lobbying and political contributions draws on peer-reviewed research published in JAMA Health Forum, JAMA Internal Medicine, and the American Journal of Political Science.
The discussion of the 2026 midterm elections draws on contemporary Reuters reporting. Information about congressional procedures and public participation is supported by official government resources.
The article distinguishes documented political expenditures and donor access from claims about legislative influence that have not been established by the cited research.
Because congressional leadership elections and related political developments are ongoing, the election and leadership sections should be reviewed whenever significant new information becomes available.
